The implant will be developed for the treatment of patients with juvenile idiopathic arthritis or young patients with congenital dysplastic hip disease.
“HSS’s clinical leadership, biomechanical engineering and innovation expertise, together with Wishbone’s experience developing technologies to serve pediatric patients, position us to improve the quality of life of these young patients who do not have many therapeutic options,” said Louis Shapiro, president and CEO of HSS. HSS chief of the surgical arthritis service Mark Figgie, MD, invented the device.
More articles on devices and implants:
Globus Medical taps into trauma market – 11 new devices receive FDA clearance
Medtronic, Mazor Robotics, Stryker & more: 13 device company notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
